The Fort Worth Press - NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

USD -
AED 3.672498
AFN 63.999702
ALL 82.464942
AMD 358.505756
ANG 1.790403
AOA 917.498647
ARS 1549.870021
AUD 1.484032
AWG 1.8025
AZN 1.696134
BAM 1.779156
BBD 2.017129
BDT 124.690139
BGN 1.77347
BHD 0.378157
BIF 3007.43672
BMD 1
BND 1.291033
BOB 11.682086
BRL 5.7845
BSD 1.001496
BTN 94.002656
BWP 14.018585
BYN 3.009424
BYR 19600
BZD 2.014218
CAD 1.43019
CDF 2317.999943
CHF 0.838915
CLF 0.025357
CLP 997.979904
CNY 6.66455
CNH 6.66546
COP 3317.23
CRC 446.292118
CUC 1
CUP 24.035623
CVE 100.306108
CZK 22.17145
DJF 178.348063
DKK 6.78993
DOP 60.867113
DZD 137.008028
EGP 53.678304
ERN 15
ETB 164.376481
EUR 0.90833
FJD 2.296799
FKP 0.758367
GBP 0.757835
GEL 2.594988
GGP 0.758367
GHS 11.732118
GIP 0.758367
GMD 73.501169
GNF 8873.120921
GTQ 7.654066
GYD 209.544342
HKD 7.846035
HNL 26.932961
HRK 6.831965
HTG 131.250142
HUF 330.815503
IDR 18233.75
ILS 3.248749
IMP 0.758367
INR 93.57705
IQD 1518.259596
IRR 1925253.9999
ISK 124.25976
JEP 0.758367
JMD 158.794125
JOD 0.708947
JPY 159.196501
KES 130.050152
KGS 87.449398
KHR 4106.5296
KMF 447.498309
KPW 900.00035
KRW 1338.809943
KWD 0.311439
KYD 0.834633
KZT 445.59873
LAK 22549.202436
LBP 89683.974965
LKR 333.298462
LRD 170.2507
LSL 16.970744
LTL 2.95274
LVL 0.60489
LYD 6.470746
MAD 9.982716
MDL 18.317444
MGA 4555.8128
MKD 55.91772
MMK 2099.8229
MNT 3605.49036
MOP 8.0932
MRU 40.667528
MUR 47.859839
MVR 15.410333
MWK 1736.583325
MXN 18.50519
MYR 4.091198
MZN 63.909632
NAD 16.970667
NGN 1346.080103
NIO 36.851561
NOK 9.64695
NPR 150.403886
NZD 1.81999
OMR 0.384499
PAB 1.001465
PEN 3.415402
PGK 4.572229
PHP 63.736022
PKR 276.920096
PLN 3.99624
PYG 6215.118421
QAR 3.660925
RON 4.854006
RSD 106.818972
RUB 82.598925
RWF 1479.507134
SAR 3.763042
SBD 8.098361
SCR 14.276828
SDG 601.518606
SEK 10.083204
SGD 1.288005
SHP 0.758581
SLE 23.049833
SLL 20969.503664
SOS 572.372042
SRD 37.4535
STD 20697.981008
STN 22.288025
SVC 8.762969
SYP 13002.000337
SZL 16.966036
THB 33.82499
TJS 9.228432
TMT 3.51
TND 3.027513
TOP 2.40776
TRY 50.417195
TTD 6.801694
TWD 32.962498
TZS 2651.997978
UAH 45.525197
UGX 4156.319079
UYU 40.6615
UZS 12027.818082
VES 914.603596
VND 25735
VUV 120.845902
WST 2.802705
XAF 595.82556
XAG 0.021012
XAU 0.0002579996
XCD 2.70255
XCG 1.8049
XDR 0.707052
XOF 595.82556
XPF 108.488699
YER 236.49594
ZAR 16.959115
ZMK 9001.1985
ZMW 20.506056
ZWL 321.999592
SSP 5946.953244
MXV 2.075993
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.

Text size:

Event Information:

Event

NanoViricides Presentation at the Biotech Showcase, San Fransisco

Day & Date

Tuesday, January 14, 2025

Time, Track & Room

2:30pm PT, Yosemite A (Ballroom Level)

Location

Hilton San Fransisco - Union Square

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Technologies available for licensing.

The Phase II-ready drug NV-387 has demonstrated extremely broad antiviral spectrum of activity in animal models, which could prove to be as revolutionary for viral infections as penicillin was for bacterial infections. This broad spectrum is because NV-387 is designed to mimic a host-side feature that is used by over 90-95% of human pathogenic viruses when they cause infection.

In light of the concerns regarding H5N1 Bird Flu and its potential spread, NV-387 is one of the most promising candidates that can respond to an Influenza pandemic. The Influenza virus would be unable to escape the NV-387 drug treatment because this drug mimics the feature on the host-side that all Influenza viruses continue to use for causing an infection, even as they evolve rapidly in the field.

NV-387 has demonstrated activity substantially superior to each of oseltamivir (Tamiflu®), peramivir (Rapivab®), and baloxavir (Xofluza®) in lethal animal models of Influenza A lung viral infection. These approved drugs as well as vaccines and antibodies are readily escaped by the virus as it evolves in the field.

NV-387 has also shown strong activity in lethal animal model studies for MPox and Smallpox treatment developments. There is no drug for the treatment of MPox infection at present. MPox Clade 1 and 1b infections have caused a continuing pandemic in the Africa that led to WHO declaring a Public Health Emergency of International Concern (PHEIC) in August 2024.

NV-387 has demonstrated cure of lethal RSV infection in animal model studies. There is no drug for the treatment of RSV infection at present, except for the last resort toxic drug ribavirin.

NV-387 has demonstrated strong activity against coronavirus lethal animal models for SARS-CoV-2 infection (COVID-19).

In addition, the Company has developed a platform that enables important non-oral drugs to be delivered as active oral drugs, which we believe is a sought after technology by Pharma companies.

The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.

This year, registered attendees can view NanoViricides' presentation live, and also access a recorded version after the event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 16th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

About NanoViricides

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

SOURCE: NanoViricides

C.M.Harper--TFWP